1. Home
  2. GFUZ vs IRWD Comparison

GFUZ vs IRWD Comparison

Compare GFUZ & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GFUZ

General Fusion Group Ltd. Common Shares

N/A

Current Price

$7.71

Market Cap

687.0M

Sector

Utilities

ML Signal

N/A

Logo Ironwood Pharmaceuticals Inc.

IRWD

Ironwood Pharmaceuticals Inc.

HOLD

Current Price

$4.29

Market Cap

713.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GFUZ
IRWD
Founded
N/A
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
687.0M
713.8M
IPO Year
2025
2009

Fundamental Metrics

Financial Performance
Metric
GFUZ
IRWD
Price
$7.71
$4.29
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$7.67
AVG Volume (30 Days)
180.8K
1.9M
Earning Date
N/A
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1400.00
EPS
N/A
0.55
Revenue
N/A
$298,276,000.00
Revenue This Year
N/A
$57.95
Revenue Next Year
N/A
$4.39
P/E Ratio
N/A
$7.76
Revenue Growth
N/A
8.88
52 Week Low
$6.08
$1.01
52 Week High
$11.00
$5.78

Technical Indicators

Market Signals
Indicator
GFUZ
IRWD
Relative Strength Index (RSI) 49.30 52.69
Support Level $6.08 $3.85
Resistance Level $10.03 $4.53
Average True Range (ATR) 0.71 0.21
MACD 0.02 -0.01
Stochastic Oscillator 43.31 61.32

Price Performance

Historical Comparison
GFUZ
IRWD

About GFUZ General Fusion Group Ltd. Common Shares

General Fusion Group Ltd is focused on developing fusion energy technology based on Magnetized Target Fusion (MTF), which combines magnetic confinement and mechanical compression to achieve fusion conditions. It operates a large-scale demonstration system, Lawson Machine 26 (LM26), intended to validate elements of its technology and support the development of commercial fusion power plants for electricity generation.

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

Share on Social Networks: